StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Alnylam Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 77.4%. For fiscal 2025 it was 81.8%, against 86.4% the year before. The highest annual figure on record is 100.0% in fiscal 2017.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202581.8%−4.6
FY2024Dec 31, 202486.4%+1.0
FY2023Dec 31, 202385.3%−1.2
FY2022Dec 31, 202286.5%+0.1
FY2021Dec 31, 202186.4%+1.4
FY2020Dec 31, 202084.9%−3.6
FY2019Dec 31, 201988.6%−9.0
FY2018Dec 31, 201897.6%−2.4
FY2017Dec 31, 2017100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202675.2%−9.0
Q2 FY2026Jun 30, 202676.9%−4.7
Q1 FY2026Mar 31, 202682.2%−6.0
Q4 FY2025Dec 31, 202575.6%−7.1
Q3 FY2025Sep 30, 202584.2%+0.6
Q2 FY2025Jun 30, 202581.6%−8.2
Q1 FY2025Mar 31, 202588.2%−0.8
Q4 FY2024Dec 31, 202482.7%−0.9
Q3 FY2024Sep 30, 202483.6%−5.8
Q2 FY2024Jun 30, 202489.8%+13.4
Q1 FY2024Mar 31, 202489.0%+1.9
Q4 FY2023Dec 31, 202383.6%−2.6
Q3 FY2023Sep 30, 202389.4%+3.2
Q2 FY2023Jun 30, 202376.4%−8.5
Q1 FY2023Mar 31, 202387.0%−2.0
Q4 FY2022Dec 31, 202286.2%−0.8
Q3 FY2022Sep 30, 202286.2%+1.2
Q2 FY2022Jun 30, 202284.9%−1.4
Q1 FY2022Mar 31, 202289.0%+2.0
Q4 FY2021Dec 31, 202187.0%+0.3
Q3 FY2021Sep 30, 202185.0%+1.6
Q2 FY2021Jun 30, 202186.3%+3.9
Q1 FY2021Mar 31, 202187.0%+0.4
Q4 FY2020Dec 31, 202086.7%+3.7
Q3 FY2020Sep 30, 202083.5%−9.1
Q2 FY2020Jun 30, 202082.4%−7.9
Q1 FY2020Mar 31, 202086.6%−3.3
Q4 FY2019Dec 31, 201983.0%−9.1
Q3 FY2019Sep 30, 201992.6%−0.8
Q2 FY2019Jun 30, 201990.3%–
Q1 FY2019Mar 31, 201989.9%–
Q4 FY2018Dec 31, 201892.1%–
Q3 FY2018Sep 30, 201893.4%–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?